Natriumfluorid (18f) Nms (Sodium Fluoride (18f))

Sodium Fluoride, the active ingredient in Natriumfluorid (18f) Nms, is a radiopharmaceutical presented as a solution for injection for intravenous use. It is employed in bone imaging to detect metastatic disease and evaluate skeletal turnover in patients.

GNH USA supplies Natriumfluorid (18f) Nms as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and imaging clinics worldwide.

Sodium Fluoride (18F) is a radiopharmaceutical used in bone imaging to assess skeletal metabolism and detect metastatic disease. - Bone metastasis detection: enables visualization of metastatic lesions in bone using PET imaging. - Skeletal imaging: provides high‑resolution images of the entire skeleton for diagnostic evaluation. - Evaluation of bone turnover: allows quantitative assessment of bone remodeling activity in research and clinical settings.

Sodium Fluoride (18F) is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Injection site pain: mild discomfort at the site of administration. - Nausea: transient feeling of queasiness after injection. - Flushing: brief warmth or redness of the skin. - Headache: mild to moderate headache reported by some patients.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure following administration. - Radiation‑induced skin injury: localized skin changes at high exposure levels.

Use of Sodium Fluoride (18F) requires careful consideration of patient safety and handling of the radiopharmaceutical. - Pregnancy: avoid use unless clearly needed, as fetal radiation exposure is unknown. - Breastfeeding: discontinue breastfeeding for an appropriate period after administration. - Renal impairment: assess kidney function before dosing, as excretion is renal. - Radiation safety: follow local regulations for handling and disposal of radioactive material. - Hypersensitivity: do not administer to patients with known allergy to fluoride compounds. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sodium Fluoride (18F) may interact with other agents that affect bone metabolism or radiotracer distribution.

Major Interactions (Avoid): - Concurrent radiopharmaceuticals: may interfere with image interpretation. - High‑dose calcium supplements: can reduce tracer uptake in bone. - Certain chemotherapeutic agents (e.g., methotrexate): may alter bone turnover and affect imaging results.

Moderate Interactions (Monitor Closely): - Bisphosphonates: may modify bone binding of fluoride. - Corticosteroids: can influence bone metabolism and tracer distribution. - Iodinated contrast agents: may affect PET image quality if administered shortly before or after the tracer.